Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06414434 · ClinicalTrials.gov registry record · Phase 1
BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma
A Phase 1 study of Liposarcoma and Recurrent Liposarcoma, sponsored by Michael Wagner, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT06414434: Recruiting Phase 1 study of Liposarcoma and Recurrent Liposarcoma, sponsored by Michael Wagner, MD.
NCT06414434 is a Phase 1 study of Liposarcoma and Recurrent Liposarcoma that is actively recruiting participants, run by Michael Wagner, MD. The registered enrollment target is 24 participants, below the 83-participant average among 13 other Liposarcoma trials with a reported enrollment target (71% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06414434, a Phase 1 study of Liposarcoma and Recurrent Liposarcoma, is actively recruiting participants, sponsored by Michael Wagner, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is testing two different doses of BTX-A51 to determine if it is safe and tolerable in participants with liposarcoma with MDM2 amplification, myxoid liposarcoma, and CIC-rearranged sarcoma. The name of the study drug used in this research study is: -BTX-A51 (a type of kinase inhibitor)
Primary Outcome
Safety and tolerability will be monitored through continuous reporting of treatment-emergent and treatment-related adverse events, laboratory abnormalities, and incidence of subjects experiencing dose modifications, delays, interruptions, or premature discontinuation of BTX-A51 due to an adverse event. Toxicities are to be assessed according to the CTCAEv5.
Conditions Studied
Interventions
- DRUG BTX-A51
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 1 |
What NCT06414434 shows while recruiting
NCT06414434 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 83-participant average among 13 other Liposarcoma trials with a reported enrollment target (71% lower).
The record links to 7 conditions, with Liposarcoma appearing as the primary indexed condition, and to 1 intervention - of which BTX-A51 is the first listed.
NCT06414434 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06414434 about?
NCT06414434 is a clinical study titled "BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma". This study is testing two different doses of BTX-A51 to determine if it is safe and tolerable in participants with liposarcoma with MDM2 amplification, myxoid liposarcoma, and CIC-rearranged sarcoma. The name of the study drug used in this research study is: -BTX-A51 (a type of kinase inhibitor)
What is the current status of trial NCT06414434?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-09-30. Estimated completion is 2027-06-01.
What conditions does trial NCT06414434 study?
This clinical trial studies the following conditions: Liposarcoma, Recurrent Liposarcoma, Unresectable Liposarcoma, Myxoid Liposarcoma, Metastatic Liposarcoma.
What interventions are being tested in trial NCT06414434?
The interventions under investigation include: BTX-A51 (DRUG).
Who is sponsoring clinical trial NCT06414434?
This trial is sponsored by Michael Wagner, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06414434 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liposarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06414434's enrollment target sits among peer trials
24 7th of 13 higher than 6 of 13 other Liposarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Liposarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
RECRUITING · Phase 1
-
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
RECRUITING · Phase 1
-
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
RECRUITING · Phase 1
-
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI